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Anovel endoproteolytic processing activity in mitochondria of erythroid cells
and the role in heme synthesis
Vijole Dzikaite,Arvydas Kanopka, Jeremy H. Brock,Arunas Kazlauskas, and O ¨ jar Melefors
The erythroid isoform of aminolevulinate
synthase (eALAS) protein is a major
control point in erythroid heme synthesis
andhemoglobinformation.Erythroidcells
were extracted from mouse blood and
bone marrow and metabolically labeled
with 35S-methionine. This was followed
by immunoprecipitation of eALAS protein
products. The results show that the
N-terminus of the expected full-length
59-kd form of the eALAS protein is
truncated in bone marrow erythroid cells
by approximately 7 kd. More differenti-
ated erythroid cells in the peripheral
blood exhibit very little of this protein
truncation. Erythroid cells from the bone
marrow were isolated using monoclonal
antibody TER-119 and were shown to
contain a unique endoprotease activity
that could cleave the eALAS protein to
the shorter form in vitro. With or without
the mitochondrial signal sequence, the
eALAS protein could serve as a substrate
for the cleavage. This cleavage renders a
functional eALAS protein and only re-
moves a domain of unclear function,
which has previously been reported to
vary in size as a result of alternative RNA
splicing. The protease activity was en-
riched from the membranes of mitochon-
dria from bone marrow cells and was
shown to be different from mitochondrial
processing peptidase, medullasin, and
other known proteases. Apart from the
mitochondrial processing peptidase that
cleaves the import signal sequence, this
is the ﬁrst description of a mitochondri-
ally located site-speciﬁc processing pro-
tease activity. (Blood. 2000;96:740-746)
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Introduction
Adult hemoglobin is made up of 2a- and 2b-globin polypeptides,
each of which contains a prosthetic heme group. Heme (a
porphyrin chelate of iron known as Fe-protoporphyrin IX) controls
translation of the globin messenger RNAs (mRNAs) by using a
heme-controlled kinase1 to phosphorylate the translation initiation
factor eIF2-alpha as well as the expression of other erythroid
genes.2,3Formationofhemeitselfinitiallyrequirestheprotoporphy-
rin IX skeleton, which is made in 7 enzymatic steps, starting with
the rate-limiting aminolevulinate synthase (ALAS) [Enzyme Cata-
logue 2.3.1.37] catalyzed reaction between glycine and succinyl-
coenzymeA(succinyl-CoA). Erythroid cells express an isoform of
ALAS (eALAS or ALAS2) in addition to the ubiquitously ex-
pressed housekeeping form ofALAS (hALAS orALAS1).4-9
eALAS and other erythroid-speciﬁc genes are induced in
nucleated erythroid progenitor cells via speciﬁc transcription
factors. Even after expulsion of the nucleus, a tight posttranscrip-
tional control of heme synthesis maintains iron and protoporphyrin
compounds at nontoxic levels despite the fact that the rate of heme
production is at least 1 order of magnitude greater in erythroid cells
than in nonerythroid cells. eALAS is believed to be the key control
point for regulating heme synthesis in reticulocytes in response to
heme, iron, or other physiological stimuli.8 Part of the regulation of
eALAS and heme synthesis has been attributed to the iron-
responsive element (IRE) in the 58 untranslated region of the
eALAS mRNA.10,11 Under low-iron conditions, iron regulatory
proteins (IRP 1 and 2) will bind to the IRE in the eALAS mRNA
and repress translation. However, increased iron or heme will
convert IRP into a nonbinding form and allow translation.12,13 IRP
has also been shown to respond to other physiological stimuli in
mammalian erythroid cells, such as nitric oxide and erythropoei-
tin,14,15 making it an important control point in hemoglobin
production. Heme also exerts a negative feedback effect on its own
synthesis; increasing heme levels appear to block import of the
eALAS protein into the mitochondria by binding to a speciﬁc cysteine-
proline rich sequence in the signal peptide.16 Heme may also exert a
negative effect on iron release from transferrin in red cells.8
Previous work on hemin and iron regulation of erythroid heme
synthesis has been mainly limited to erythroid cell lines. The levels
of hemoglobin are considerably lower in these cell lines, and the
genes of the heme synthesis pathway are not fully induced
compared with natural hemoglobin-producing cells in the body.17
During studies on eALAS regulation in erythropoietic cells, we
observed that 2 forms of the protein were sometimes detected by
immunoprecipitation. Because there is no previous evidence of
eALAS heterogeneity, we decided to investigate the origins of
these 2 forms.
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Preparation of cell lysates
Balb/C mice (6-8 weeks old) were killed by cervical dislocation following
local ethical guidelines. Bone marrow cells were extracted from the femurs
and added to minimal essential medium (MEM) with Earle salts or
Dulbecco modiﬁed Eagle medium (DMEM) without methionine (Gibco
BRL, Paisley, UK) using a 27-and-3/4–gauge needle. Suspensions of spleen
or liver cells were prepared by gently mashing the nonperfused excised
organ on a nylon net and discarding sedimented debris. Peripheral blood
was collected into heparinized plastic tubes. All cells were washed by
low-speed centrifugation in serum-free medium and routinely applied to a
Ficoll-Hypaque gradient (Ficoll-Hypaque Plus; Pharmacia, Uppsala, Swe-
den) to enrich reticulocytes. The cells were diluted to 3 mL in MEM,
carefully overlaid on an equal volume of Ficoll-Hypaque in a 15-mLplastic
tube, and centrifuged at 30g for 90 minutes at 4°C. The high- and
low-density fractions of cells were removed with a Pasteur pipette, washed
3 times, and resuspended in IMDM without methionine with 10% fetal calf
serum (FCS), L-glutamine, and streptomycin/penicillin G (Gibco).
The cells from blood and bone marrow were stained with May-
Gru ¨nwald Giemsa (MGG) or methylene blue stain and examined by
microscopy. Peripheral blood contained 2.7% reticulocytes. Following
Ficoll-Hypaque separation, the lower fraction contained 4.0% reticulocytes,
whereas the upper fraction was virtually depleted of reticulocytes. Bone
marrow cells contained 32% erythropoietic cells; of the erythroblasts, 30%
were proerythropoietic; 49%, basophilic; 12%, polychromatic; and 9%,
orthochromatic. Although we routinely used the lower fraction from the
Ficoll-Hypaque gradient in our experiments, separation of bone marrow
cells does not give a clear enrichment of the protease activity, which may
also be present in several erythroblast stages that separate into the upper
Ficoll-Hypaque fraction. To acquire labeled extracts, we used the following
concentrations of 35S-L-methionine as indicated: 3.7 3 1013 Bq or 0.37
MBq/µL (1000 Ci/mmol or 10 µCi/µL) (NEG-009A; New England Nuclear,
Boston, MA). Labeled cells were washed twice in ice-cold phosphate-
buffered saline (PBS) and resuspended for 30 minutes on ice in ratio
immunoprecipitation assay (RIPA) detergent buffer containing 0.15 mol/L
sodium chloride (NaCl); 1% Nonidet P-40; 0.5% deoxycholate; 0.1%
sodium dodecyl sulfate (SDS); 50 mmol/L Tris HCl (trishydroxymethyl
aminomethane hydrochloride) (pH 7.5); and either the LPPA protease
inhibitors, 1 µmol/L leupeptin, 1 µmol/L pepstatin, 2 mmol/L Pefabloc, and
0.2 µmol/L aprotinin, or Complete Mini tablets (all from Boehringer-
Mannheim, Mannheim, Germany). After suspension on ice, the cells were
centrifuged at 15 000g at 4°C to remove debris. Nonlabeled lysates of
tissues were prepared without prior labeling. The protein content of lysates
was analyzed by standard methods, and comparable amounts were used in
experiments.
To isolate erythroid and granulocyte subpopulations, respectively, from
bone marrow cell suspension, we used the rat monoclonal antibodies
(mAbs) TER-11918 (PharMingen, San Diego, CA) and CL8991AP19
(Cedarlane, Quebec, Canada). Bone marrow cells from 2 mice (60 3 106
cells) were diluted in complete DMEM and incubated with 4 µL TER-119
(0.5 mg/mL) or CL8991AP (1 mg/mL) for 60 minutes at 4°C in a rotator.A
120-µL aliquot of a 50% suspension of Dynabeads (No. 110.07; Dynal AS,
Oslo, Norway) that recognize rat immunoglobulin G (IgG) were added, and
the samples were incubated for another 30 minutes at 4°C. The beads
with attached cells were isolated and washed 3 times in complete DMEM
using the supplied magnetic device, and the lysates were prepared as
described above. Aliquots of separated cell populations were stained with
MGG, and microscopic inspection conﬁrmed a strong enrichment of the
speciﬁc cell type.
Immunoprecipitation
Lysates were routinely precleared of endogenous protein A–binding Ig
chains by incubation on a rotator with 50-µLof a 50% suspension of protein
A CL-4B Sepharose beads (Pharmacia) for 1 hour at 4°C in a total volume
of 500 µL. Titrated amounts of speciﬁc antisera against eALAS20 were
rotated for 3 hours at 4°C in a total volume of 500 µL. This was followed by
incubation with 50 µL beads for 1 hour. In the indicated experiments, cold
lysates were included in the reaction. Thereafter, beads were washed at low
speed 3 times in 1 mLRIPA, resuspended in Laemmli loading buffer, heated
at 95°C for 10 minutes to elute proteins, and loaded on 12% SDS-PAGE
(polyacrylamide gel electrophoresis), which was ﬁxed and exposed to
X-ray ﬁlm or phosphor imager screens. The protein sizes were determined
by parallel electrophoresis of commercial molecular weight standards. The
presence of the shorter form of eALAS could not be explained by
nonspeciﬁc protein degradation. No changes in the ratio between the
different eALAS forms were observed when parallel reactions were
subjected to different lengths of incubation, different temperatures, or the
addition of protease inhibitors. Using this antiserum, we did not detect
cross-reaction with hALAS or any other proteins of nonerythroid cells.20
Subfractionation of mitochondria
Bone marrow or blood cells were separated on 3-mLFicoll-Paque cushions
(Pharmacia) by centrifugation at 900g for 1 hour at 4°C. The high-density
fraction was washed 3 times and resuspended in 1 mL methionine-free
DMEM. During labeling experiments, the cells were incubated with
35S-methionine for 3 hours at 37°C, and the cells were then washed in PBS.
The cells were subsequently washed twice in ice-cold bufferA(250 mmol/L
sucrose, 50 mmol/L Tris HCl [pH 7.4], and 1 mmol/L EDTA [ethylenedi-
amine tetraacetic acid]) with protease inhibitors. The cells were resus-
pended in 3 mL buffer A and then lysed by sonication (Branson Sonic-
Power B-15P Soniﬁer, Danbury, CT) with 2 bursts of 10 seconds each
(setting, 5). Lysis was conﬁrmed by microscopic inspection. To remove
debris, the lysate was centrifuged twice at 900g for 20 minutes at 4°C. To
pellet mitochondria, the supernatant was subsequently centrifuged at
12 000g for 25 minutes at 4°C. The resulting supernatant was deﬁned as
‘‘cytosol fraction.’’The mitochondrial pellet was washed twice in ice-cold
buffer B (250 mmol/Lsucrose, 10 mmol/LTris HCl [pH 7.4], and 1 mmol/L
EDTA) and resuspended in RIPA(‘‘crude mitochondrial lysate’’).
For further subfractionation, the mitochondrial pellet was resuspended
in 1 mL buffer B and sonicated on ice 3 times for 30 seconds each time
(setting, 5) followed by a 12 000g centrifugation for 15 minutes to sediment
intactmitochondria.Thesuspensionorsonicatewascentrifugedat250 000g
for 60 minutes at 4°C. The supernatant was recentrifuged to remove debris
and was deﬁned as the ‘‘matrix fraction’’ (although it might also include
intermembrane space proteins). The pellet was washed in buffer B and
deﬁned as the ‘‘membrane fraction.’’Fractions were tested by Western blot
analysis for purity by using antisera against the membrane-bound succinate
dehydrogenase21 or the matrix-bound mitochondrial transcription factor A
(MTA) protein22 (data not shown). To further enrich the mitochondrial
population, we loaded the mitochondrial pellet (see above) on a gradient
containing 30% Percoll (Pharmacia, Uppsala, Sweden), 0.25 mol/Lsucrose,
5 mmol/L Tris (pH 7.4), and 0.5 mmol/L EDTA. This was followed by
centrifugation at 60 000g for 60 minutes at 4°C, and then the speciﬁc
mitochondrial fraction (‘‘pure mitochondria’’) was collected.
In vitro reconstitution
Plasmids pPre–ALAS-E-minor and pPre–ALAS-E-major express 2 natural
variants of murine pre-eALAS under the control of a phage T3 promoter in
the pBluescript vector.16 The protein derived from pPre–ALAS-E-minor is
identical to the protein derived from pPre–ALAS-E-major except that it
lacks amino acids 61-75 of the pre-eALAS sequence. Plasmids were
linearized with BamHI and transcribed and translated in vitro in the
presence of 35S-methionine in the Flexi Rabbit reticulocyte lysate system
(Promega, Madison, WI) according to the manufacturer’s instructions. The
products were dialyzed against 10 mmol/L HEPES-KOH (4-(2-Hydroxy-
ethyl)-1-piperazineethanesulfonic acid) (pH 7.4) and 0.2 mmol/L DTT. We
mixed 0.2 µg dialyzed 40%-60% ammonium sulfate precipitation fraction
of a bone marrow crude mitochondria lysate with 9 µL in vitro translated
eALAS protein in the above buffer (with 0.5 mmol/L MnCl2). This was
completed in a total volume of 20 µL and incubated at 27°C for 60 minutes
before gel separation.
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To study eALAS during differentiation, we metabolically labeled
ex vivo cells from mouse peripheral blood and bone marrow with
35S-methionine. As expression of eALAS is limited to erythroid
cells, detergent lysates were prepared (in the strong ionic detergent
RIPA) and used directly, without further enrichment of erythro-
blasts, for immunoprecipitation with an antiserum against murine
eALAS. Immunoprecipitation of eALAS from lysates of peripheral
blood (Figure 1) revealed an expected 59-kd double band (see
below) representing the full-length forms of eALAS. A weaker
65-kd band, presumably corresponding to the precursor before
cleavage of the mitochondrial signal peptide, was also revealed.
Both have been previously demonstrated in mouse erythroleukemia
(MEL) cells with this antiserum.20
In addition, a speciﬁc shorter form of the eALAS (eALAS-
short) protein, approximately 52 kd in size, was precipitated from
blood cells. This was consistently the only form to be expressed in
bone marrow cell lysates. In blood cell lysates the relative amount
of the eALAS-short protein varied between experiments, ranging
from undetectable to being equimolar to the 59-kd form. This
observed pattern thus suggested a loss of eALAS-short and the
appearance of the 59-kd form with the maturation of the erythroid
cells. It is important to note that the ex vivo metabolic labeling
enables us to detect only de novo formation of proteins and not
steady state levels of the 2 forms of eALAS in the blood. However,
a de novo pool of the 59-kd form of eALAS in the peripheral blood
reticulocyte could rapidly form, provided the eALAS protein turns
over at a similar speed as the nonerythroid form of ALAS (half-life,
approximately 35 minutes).23
There was no obvious difference in the eALAS mRNA pattern
in blood and bone marrow (data not shown), as seen using
high-resolution Northern blot gels and reverse transcriptase–
polymerase chain reactions (RT-PCRs). This indicates that the
eALAS-short protein arose by a posttranslational event. To deter-
mine whether posttranslational proteolytic cleavage might be
responsible for the short form, we coincubated a ‘‘cold’’ bone
marrow lysate and a radiolabeled blood cell lysate during immuno-
precipitation. Figure 2 demonstrates that we can immunoprecipi-
tate a shorter form of eALAS, identical in size to the 52-kd
Figure 1. eALAS protein synthesis in different erythroid tissues. Peripheral
blood and bone marrow were diluted with DMEM without methionine to 3 mL,
separated on 3 mL Ficoll-Hypaque gradients, resuspended in 1 mL medium (blood,
1.5 3 108 cells; bone marrow, 1.9 3 107 cells), and incubated with 7.4 MBq (200 µCi)
35S-methionine for 3 hours. Detergent lysates were prepared, and eALAS and gel
separation were immunoprecipitated. The arrows indicate the presumed pre-eALAS,
the 59-kd form, and the herein described 52-kd eALAS-short.
Figure 2. Cleavage of eALAS by a proteolytic activity in bone marrow erythroid
cells. (A) Blood (1 mL) was separated on a 3-mL Ficoll-Hypaque gradient. The
high-density fraction was resuspended in medium and divided into 2 tubes to which
7.4 MBq (200 µCi) 35S-methionine was added. A 300-µL nonlabeled bone marrow
lysate (1.5 3 108 cells) (lane 2) or medium alone (lane 1) was added. Both samples
were incubated at 37°C for 3 hours, and eALAS proteins were subsequently
immunoprecipitated and gel-separated. (B) Erythroid and granulocytic cells were
isolated from the bone marrow by mAbs coupled to magnetic beads (‘‘Materials and
methods’’). We incubated 80-µg lysates from these fractions with a labeled blood
lysatefor30minutesat37°C,andeALASproteinsweresubsequentlyimmunoprecipi-
tated and gel-separated. The far-right lane represents a lysate after depletion of
erythroid cells.
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originates from the 59-kd form of the protein in the blood cells.
In addition, a shorter band of 5-10 kd accumulated, al-
though it remains unclear if this product is related to the cleav-
age process.
To test if this protease activity was present in erythroid cells, we
next isolated such cells from the bone marrow by employing
magnetic beads and the erythroid-speciﬁc mAb TER-119.18 In
parallel we isolated granulocytes with this technique using the
mAb CL8991AP,19 as such cells contain potent lysosomal prote-
ases that could be released during lysis and cleave other proteins.
When we tested equal amounts of lysates from erythroid and
granulocyte cells for protease activity, it clearly showed that
erythroid cells contained this protease activity, whereas there was
no activity detected in granulocytes (Figure 2B). The claim of an
erythroid-speciﬁc activity was further supported by the fact that
there was no activity retained in a lysate from bone marrow cells
depleted of erythroid cells.
To localize the protease activity to a cell compartment, bone
marrow cells were lysed by sonication and further subfrac-
tionated by differential centrifugation into a mitochondrial and a
cytosolic fraction. To exclude the possibility that the protease
activityresidedinotherorganellescosedimentingwiththemitochon-
dria, crude mitochondria were also separated on a density gradient,
and the speciﬁc mitochondrial fraction was collected. The testing
of this and other fractions for protease activity showed clearly that
the activity resides in the mitochondria (Figure 3A). We also
sonicated the mitochondria and divided them into a membrane and
a matrix fraction. From testing these for the ability to cleave the
59-kd form of the eALAS protein, we could further localize the
protease activity to the membrane fraction (Figure 3B). The
mitochondrial membrane was additionally washed with up to 1
mol/L of chaotrophic salts without loss of protease activity,
indicating that it was an integral part of the membranes (data
not shown).
Figure 3. Fractionation of protease activity. (A) Lysates of 35S-methionine–labeled
blood cells were prepared (‘‘Materials and methods’’). Equal amounts were incubated
alone or mixed with nonlabeled lysates of bone marrow cells and subfractions of 80
µg each. The mixtures were immunoprecipitated for 3 hours at 4°C with standard
protease inhibitors before gel separation. (B) Bone marrow crude mitochondria (mit.)
were further subfractionated (80 µg each) into a membrane and matrix fraction and
were analyzed the same way. (C) Nonlabeled 80-µg lysates each of bone marrow,
spleen, and liver tissue were mixed with the labeled blood lysate and analyzed the
same way.
Figure 4. Inhibition of protease activity. (A) Bone marrow cells were aliquoted into
6 different tubes containing RIPA and the indicated inhibitors (50 µg/mL elastatinal,
0.5 mg/mL alpha-1-antitrypsin, 5 mmol/L EDTA, and leupeptin/Pefabloc/pepstatin/
aprotinin [LPPA]). A lysate of 35S-methionine–labeled blood cells (300 µL each) was
added, and the reaction was immunoprecipitated for 3 hours at 4°C before gel
separation. (B) The experiment was repeated with varying amounts of alpha-1-
antitrypsin (0.1, 0.25, 0.5, and 1 mg/mL, shown in lanes 3-6, respectively).
35S-methionine–labeled bone marrow cells were lysed in RIPA with or without 0.5
mg/mL alpha-1-antitrypsin followed by immunoprecipitation for 1 hour at 4°C without
any preclearing (lanes 7 and 8).
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tested them for the presence of proteolytic activity in a similar way.
No protease activity could be detected in these tissues under the
conditions we used (Figure 3C).The bone marrow protease activity
was potent in a strong detergent (RIPA) and insensitive to several
inhibitors of serine, cysteine, and aspartic proteases or metallopro-
teases as well as high levels of EDTA when these agents were
added to lysates at the indicated concentrations. We could only
observe inhibition of cleavage with high amounts of alpha-1-
antitrypsin (Figure 4A). A dose response to alpha-1-antitrypsin,
which showed a proportional increase in the substrate and a
decrease in the product, was observed (Figure 4B). To exclude the
possibility that cleavage was due to a proteolytic activity that was
released from another cell type (or organelle) during lysis of the
bone marrow cells, we included alpha-1-antitrypsin in the lysis
buffer. But we could still only demonstrate the cleaved form
(Figure 4B), which shows that the short form was not an artifact
during preparation. This conclusion was further consolidated by
mixing labeled blood and bone marrow cells before lysis in RIPA
with alpha-1-antitrypsin, as in the latter experiment. There was no
observed cleavage in the 59-kd blood eALAS protein, which
served as an internal probe in the lysate to exclude the presence of a
protease (data not shown).
Murine eALAS mRNA can be alternatively spliced to a longer
form (85% of the eALAS mRNA amount) and a shorter form. The
shorter form results in a preprotein that lacks amino acids 61-75.24
We have not performed experiments speciﬁcally aimed to demon-
strate these 2 mRNAs in our system, but we believe that the double
band observed in the immunoprecipitations of the 59-kd form of
eALAS on high-resolution gels (Figure 1) is likely to correlate to
this difference of 15 amino acids. We translated in vitro these 2
pre-eALAS mRNAs in a rabbit reticulocyte lysate in the presence
of 35S-methionine and determined 2 slightly different 65-kd bands
after SDS-PAGE (Figure 5). Both preproteins could be cleaved by
lysates from bone marrow mitochondria to the same size band,
identical to the shorter form of eALAS, because the 15 amino acids
are in the part which is cleaved off (Figure 5). This demonstrated
that cleavage occurs at the N-terminal region and not the C-
terminal end of the protein. The N-terminal region of the human
eALAS protein is also variable as a result of alternative splicing25
(Figure 6). The reason behind the alternative splicing in mouse and
human has not been elucidated, but it is notable that this region
seems to be the subject of more than one type of regulation. This
N-terminal region is unique to the erythroid form of ALAS, unlike
the rest of the protein, which is highly homologous with the
housekeeping isoform. The N-termini of the eALAS protein are,
however, homologous between mouse, human, and rat (Figure 6),
which suggests that a similar type of cleavage could occur in other
mammals. A recent report demonstrated the presence of a fully
active shorter form of eALAS, approximately 49 kd, in human
reticulocytes, but this was not investigated further.26
The 52-kd eALAS-short protein in the bone marrow must be
functional, as it is the only form of eALAS made in this tissue, and
bone marrow erythroid cells can synthesize heme. The catalytic
activity is conﬁned to the C-terminal part of the mammalian
eALAS protein.4-8 Deletion of the ﬁrst 56 N-terminal amino acids
of the murine eALAS still allows an active protein in Escherichia
coli,27 and truncation of the 83 N-terminal amino acids of the rat
eALAS protein does not impede function in vitro28 (Figure 6). The
observed cleaved form of eALAS is indistinguishable in size from
the truncated protein27 expressed in E coli on high-resolution gels
(data not shown), and it is therefore very likely to be enzymatically
active. The localization of the shorter form of eALAS to the
mitochondria also indicates that it may be functional.
The eALAS protein domains involved in the binding (or
catalysis) of the cofactor pyridoxal 58-phosphate (Vitamin B6) are
not in the N-terminal region and should not be directly affected by
cleavage.29 Although the part which is cleaved off is not typically
lipophilic, it may serve, directly or via another protein, as an anchor
to the membrane. Electron microscopy of the housekeeping form of
ALAS suggests it is associated with the mitochondrial inner
membrane facing the matrix,30 possibly by being anchored to the
succinyl-CoA synthase beta-subunit.31 To investigate the location
of the 59-kd and eALAS-short forms of eALAS, we labeled
erythroid cells from blood with 35S-methionine, ruptured them by
sonication, and isolated the mitochondria, which were divided into
a membrane and a matrix fraction.The subsequent immunoprecipi-
tation of eALAS clearly demonstrated that both forms of eALAS
were present in the mitochondrial membrane fraction (Figure 7).
The location of both the protease activity and its product in the
membrane suggests that cleavage takes place in the mitochondrial
membrane in conjunction with the import of the preprotein. This
would predict that cells harboring protease activity would not
produce a 59-kd form of eALAS, and this could be the reason that
we were unable to detect any of this form in bone marrow cells.
Figure 5. Proteolytic cleavage of in vitro translated eALAS. In vitro translated
eALAS proteins representing the 2 natural splice variants pre–ALAS-E minor and
pre–ALAS-E major were incubated alone (lanes 1 and 2) or with a bone marrow
(b.m.) mitochondrial lysate (lanes 3 and 4) for 60 minutes at 27°C before gel
separation.Alabeled blood lysate was included as a control (lane 5).
Figure 6. The N-termini of the pre-eALAS protein from
mouse, human, and rat. The downward arrow indicates
mitochondrial processing peptidase (MPP) cleavage of
the signal peptide.16 The reported cleavage is estimated
to be within the boxed region. Horizontal bars show amino
acids affected by alternative splicing: 15 amino acids (posi-
tions 61-75) for mouse eALAS24 and 37 amino acids
(positions 102-138) for human eALAS.25 The bent arrow
marks the N-terminus of the functional protein expressed
from plasmid pTAD-ALAS2,27 and the upward arrow
marks the N-terminus for a functional rat eALAS in vitro.28
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We describe a speciﬁc truncation of the erythroid isoform ofALAS
that takes place in erythroid cells in the bone marrow. The function
of the shorter form of eALAS has yet to be established, but one can
assume that an altered function of the eALAS protein will serve to
modulate heme synthesis.
Our data argue against a direct role of the cleaved N-terminus in
membrane anchoring, although it is still possible it could serve as a
binding site for other molecules. It is noteworthy that this sequence
contains a typical heme binding site,16 suggesting a mechanism for
end-product control of the eALAS protein. Such a contention may
also be supported by the fact that this heme-binding site is lost with
the alternative splicing of eALAS mRNA.24 It could also be that
cleavage of the N-terminus results in a loss of the ability of the
eALAS protein to homodimerize. Yet other reasons for the
shortening of eALAS may be the changes in eALAS protein
stability or enzyme activity.
We believe there could be reasons why heme synthesis is
controlled differently in bone marrow and peripheral blood.
Excessive amounts of iron or heme easily result in the formation of
aggressive free radicals via the Fenton reactions,32 which could
lead to cell damage and cell transformation. Nucleated erythro-
blasts in the bone marrow could sustain an increased risk of
erythroleukemic cell transformation. Thus a more stringent control
of heme formation is needed. However, anucleate reticulocytes
(which continue to synthesize proteins after entering the
bloodstream) cannot transform, but they need a highly efficient
hemoglobin synthesis and, as a result, might have less need of
avoiding oxidative stress damage.
Some types of sideroblastic anemias are caused by point
mutations in the eALAS gene,33 and 1 mutation evidently affects
processing of the pre-eALAS protein.34 In other anemias, the
reduced hemoglobin formation and the unclear molecular basis
may also be associated with eALAS. For example, in the anemia of
chronic disease (ACD), lower hemoglobin synthesis in erythro-
blasts was correlated to a reduced eALAS activity.35
This is the ﬁrst description of an endoproteolytic site-speciﬁc
processing activity in mitochondria, apart from proteases involved
in cleavage of the import signal peptide.36-39The protease activity is
active in a strong ionic detergent, has no clear dependence on
chelatable metals, and is not affected by most common protease
inhibitors.Together with tissue speciﬁcity and the speciﬁc localiza-
tion to the mitochondrial membrane fraction, we conclude that this
protease activity must be different from known endoproteases in
the mitochondria, such as mitochondrial processing peptidase
(MPP) and mitochondrial intermediate peptidase (MIP), both of
which are instrumental in cleavage of the signal peptide.40 An
elastase-like protein (medullasin) from bone marrow was previ-
ously reported to inactivate aminolevulinate synthase.41 Medullasin
was later shown to be identical in sequence to neutrophil elas-
tase.42-43 Unlike the present protease activity, it resides in lyso-
somes of granulocytes and is readily inhibited by elastatinal.
Testing of puriﬁed medullasin and neutrophil elastase on the
eALAS substrates did not reveal any similar cleavage (data
not shown).
The protease activity seems to be tissue-speciﬁc, as we have not
observed it in lysates from tissues other than bone marrow.We have
further limited the activity to the erythroid cells in the marrow.This
argues that there must be a limited number of targets for this
protease activity. We also have not observed any changes in the
protein proﬁles in total lysates under conditions that allow cleavage
of the eALAS protein.
Many disorders affect hemoglobin function, and eALAS plays a
pivotal role in the de novo formation of hemoglobin. A future
challenge thus lies in identifying the speciﬁc function of the
eALAS-shortprotein.Anotherissuewillbethefurthercharacteriza-
tion and regulation of the tissue-speciﬁc protease activity, as this
might enable us to understand the switch between the long and
short forms of eALAS.
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